Maxim Group Downgrades BioLineRx (BLRX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Roth Remains Positive on BioLineRx (BLRX) Following Q2 Report, CEO Succession
August 11, 2016 11:46 AM EDTRoth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q2 results and appointment of a new CEO, as announced early Thursday.
Analyst Joseph Pantginis commented, The company has several important catalysts slated by year-end, which should be able to address the recent... More
BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones
August 11, 2016 7:19 AM EDTBioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07).
Expected upcoming significant milestones for remainder of 2016:
Initiation of Phase 2a study in pancreatic cancer, under immuno-oncology collaboration with Merck, following expected regulatory approval in Q3... More
